AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...

Investing.com - AbbVie (NYSE: ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia ...

US pharma group says patients who took Emraclidine in clinical trials failed to show a significant decline in symptoms ...

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia – – Topline data from 1-year open-label extension (OLE) trial now expected in December 2024 – ...

pointing to the recent Food and Drug Administration approval of the company's schizophrenia drug Cobenfy. AbbVie's emraclidine results could expand Cobenfy's first-mover advantage and ultimate ...

Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie ...

The S&P 500 added 0.1% on Monday, Nov. 11, 2024, closing above the 6,000-point milestone as investors continued to weigh the ...

Reviva Pharmaceuticals (RVPH) announced an enrollment update to the ongoing 1-year open-label extension, OLE, study evaluating the long-term safety and tolerability of brilaroxazine in patients with ...